8-K: Tyra Biosciences Reports Positive 2024 Financial Results and Highlights Clinical Progress

Tyra Biosciences announces positive financial results for 2024, highlighting the clearance of three INDs by the FDA and a strong cash position extending into 2027.

Summary

• Tyra Biosciences reported its fourth quarter and full year 2024 financial results.
• Three Investigational New Drug (IND) applications were cleared by the US FDA for TYRA's proprietary precision small molecules.
• TYRA-300 will be evaluated in three Phase 2 studies: SURF302 for Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC), BEACH301 for pediatric achondroplasia (ACH) and SURF301 for metastatic urothelial cancer (mUC).
• The company's cash, cash equivalents, and marketable securities totaled $341.4 million at the end of 2024, providing a runway through at least 2027.
• The company reported interim clinical proof-of-concept results in metastatic urothelial cancer (mUC) patients from the SURF301 study.
• At 90 mg QD, 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved a confirmed partial response (PR), with 100% disease control rate and sustained duration of activity.
• TYRA-200 advanced to Phase 1 SURF201 study.
• TYRA-430 cleared Phase 1 IND with US FDA for the SURF431 study.
• The company strengthened its leadership team and Board of Directors with key appointments.
• Research and development expenses for the full year 2024 were $80.1 million, compared to $62.5 million for the same period in 2023.
• General and administrative expenses for the full year 2024 were $24.1 million, compared to $17.4 million for the same period in 2023.
• The net loss for the full year 2024 was $86.5 million, compared to $69.1 million for the same period in 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, driven by strong financial results, clinical progress, and regulatory milestones. However, increased expenses and net losses temper the overall sentiment.

Positives

• The company has a strong cash position of $341.4 million, providing a runway through at least 2027.
• Three INDs were cleared by the FDA, indicating regulatory progress for TYRA's drug candidates.
• TYRA-300 showed promising anti-tumor activity in mUC patients, with a 54.5% confirmed partial response rate in the SURF301 study.
• The company is advancing TYRA-300 into three Phase 2 studies, expanding its clinical development program.
• The leadership team and Board of Directors have been strengthened with key appointments.
• TYRA-200 and TYRA-430 are progressing through clinical trials.

Negatives

• The company reported a net loss of $86.5 million for the full year 2024, compared to a net loss of $69.1 million for the same period in 2023.
• Research and development expenses increased to $80.1 million for the full year 2024, compared to $62.5 million for the same period in 2023.
• General and administrative expenses increased to $24.1 million for the full year 2024, compared to $17.4 million for the same period in 2023.

Risks

• Clinical trial results, including the interim results from the SURF301 study, are not necessarily indicative of final results.
• The development of drugs based on the SNP platform is novel and unproven, and may not lead to successful product candidates.
• The company is dependent on third parties for manufacturing, research, and preclinical testing.
• Unexpected adverse side effects or inadequate efficacy of product candidates may limit their development, regulatory approval, and/or commercialization.
• Unstable market and economic conditions may adversely affect the company's business and financial condition.

Future Outlook

Tyra Biosciences expects its current cash, cash equivalents, and marketable securities to allow it to execute on its plans through at least 2027. The company anticipates dosing the first child with achondroplasia with TYRA-300 in Q2 2025, dosing the first NMIBC patient with TYRA-300 in Q2 2025, and dosing the first HCC patient with TYRA-430 in Q2 2025.

Management Comments

• Todd Harris, CEO of TYRA, stated that 2024 was a momentous year, highlighted by positive interim results from the SURF301 study.
• Todd Harris expressed strong conviction in TYRA-300 and the company's diligence in advancing it for multiple high-value indications.

Industry Context

Tyra Biosciences is focused on developing next-generation precision medicines targeting FGFR biology, a field with increasing interest and competition. The company's SNP platform aims to differentiate its approach by predicting genetic alterations that cause resistance to existing therapies. The progress of TYRA-300 in multiple Phase 2 studies positions the company to potentially address unmet needs in oncology and skeletal dysplasia.

Comparison to Industry Standards

• The 54.5% confirmed partial response rate in FGFR3+ mUC patients in the SURF301 study is competitive compared to other FGFR inhibitors in development.
• The company's cash runway through at least 2027 provides a strong financial foundation compared to many other clinical-stage biotechnology companies.
• Competitors in the FGFR inhibitor space include companies like Incyte (Pemazyre), QED Therapeutics (Futibatinib), and BridgeBio Pharma (BBP-398).
• Tyra's approach of targeting specific FGFR alterations and resistance mutations aligns with the broader industry trend towards precision medicine.

Management Changes

Stakeholder Impact

• Shareholders: The positive clinical and financial updates are likely to be viewed favorably by shareholders.
• Employees: The company's growth and strong financial position provide job security and potential for career advancement.
• Patients: The development of new therapies for cancer and skeletal dysplasia offers hope for improved treatment options.
• Suppliers: The company's increased R&D spending may lead to increased business opportunities for suppliers.
• Creditors: The company's strong cash position reduces credit risk for creditors.

Next Steps

• Dose first child with achondroplasia with TYRA-300 in BEACH301 in Q2 2025.
• Dose first NMIBC patient with TYRA-300 in SURF302 in Q2 2025.
• Dose first HCC patient with TYRA-430 in SURF431 in Q2 2025.
• Continue advancing TYRA-200 in the Phase 1 SURF201 study.

Key Dates

Keywords

TYRA Biosciences, FGFR, TYRA-300, TYRA-200, TYRA-430, Clinical Trials, Precision Medicine, Oncology, Achondroplasia, NMIBC, mUC, FDA, IND